Igor Makhlin

415 total citations
18 papers, 247 citations indexed

About

Igor Makhlin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Igor Makhlin has authored 18 papers receiving a total of 247 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 5 papers in Cancer Research. Recurrent topics in Igor Makhlin's work include Advanced Breast Cancer Therapies (5 papers), Breast Cancer Treatment Studies (3 papers) and Cancer Treatment and Pharmacology (2 papers). Igor Makhlin is often cited by papers focused on Advanced Breast Cancer Therapies (5 papers), Breast Cancer Treatment Studies (3 papers) and Cancer Treatment and Pharmacology (2 papers). Igor Makhlin collaborates with scholars based in United States, Israel and Germany. Igor Makhlin's co-authors include Kevin R. Fox, Xuan Yuan, Andrea C. Baines, Karin J. Blakemore, Arthur J. Vaught, Evan M. Braunstein, Robert A. Brodsky, Jagar Jasem, C. John Sperati and Shruti Chaturvedi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Igor Makhlin

16 papers receiving 242 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Igor Makhlin United States 8 79 73 56 53 51 18 247
Irene Chong United Kingdom 8 151 1.9× 46 0.6× 17 0.3× 43 0.8× 22 0.4× 24 311
Monica Onorati Italy 9 138 1.7× 44 0.6× 27 0.5× 91 1.7× 33 0.6× 36 324
Craig Vargo United States 8 172 2.2× 102 1.4× 23 0.4× 114 2.2× 28 0.5× 20 340
Amy Guppy United Kingdom 6 105 1.3× 38 0.5× 21 0.4× 80 1.5× 9 0.2× 10 298
Nazir Jamal Canada 6 101 1.3× 65 0.9× 24 0.4× 92 1.7× 38 0.7× 9 270
Alpaslan Özgün Türkiye 10 214 2.7× 56 0.8× 116 2.1× 73 1.4× 45 0.9× 27 372
Alessandra Bologna Italy 12 288 3.6× 74 1.0× 47 0.8× 118 2.2× 8 0.2× 37 421
Raj Nagarkar India 5 101 1.3× 38 0.5× 44 0.8× 111 2.1× 5 0.1× 33 257
Woon Sup Han South Korea 12 200 2.5× 119 1.6× 36 0.6× 158 3.0× 10 0.2× 34 435
Mojca Persic United Kingdom 6 147 1.9× 70 1.0× 32 0.6× 103 1.9× 7 0.1× 12 345

Countries citing papers authored by Igor Makhlin

Since Specialization
Citations

This map shows the geographic impact of Igor Makhlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Igor Makhlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Igor Makhlin more than expected).

Fields of papers citing papers by Igor Makhlin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Igor Makhlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Igor Makhlin. The network helps show where Igor Makhlin may publish in the future.

Co-authorship network of co-authors of Igor Makhlin

This figure shows the co-authorship network connecting the top 25 collaborators of Igor Makhlin. A scholar is included among the top collaborators of Igor Makhlin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Igor Makhlin. Igor Makhlin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Feigin, Evgeny, et al.. (2025). On reduced arc spaces of toric varieties. Algebra & Number Theory. 19(2). 313–363.
2.
Makhlin, Igor, Lesley Fallowfield, N. Lynn Henry, et al.. (2024). Targeted Therapies, Sequencing Strategies, and Beyond in Metastatic Hormone Receptor–Positive Breast Cancer: ASCO Guideline Clinical Insights. JCO Oncology Practice. 21(2). 140–144. 8 indexed citations
3.
Makhlin, Igor, Biniyam G. Demissei, Ralph B. D’Agostino, et al.. (2024). Statins Do Not Significantly Affect Oxidative Nitrosative Stress Biomarkers in the PREVENT Randomized Clinical Trial. Clinical Cancer Research. 30(11). 2370–2376. 6 indexed citations
4.
Leone, José Pablo, Kathryn J. Ruddy, Naim U. Rashid, et al.. (2024). ETHAN: A phase II study comparing different endocrine therapies for male breast cancer.. Journal of Clinical Oncology. 42(16_suppl). TPS632–TPS632.
5.
6.
Chen, Saisai, Christopher J. Sterner, George K. Belka, et al.. (2023). PAQR8 promotes breast cancer recurrence and confers resistance to multiple therapies. Breast Cancer Research. 25(1). 1–1. 13 indexed citations
7.
DeMichele, Angela, Amy S. Clark, Lauren J. Bayne, et al.. (2023). 244MO A phase II trial targeting disseminated dormant tumor cells with hydroxychloroquine, everolimus or the combination to prevent recurrent breast cancer (“CLEVER”). Annals of Oncology. 34. S281–S281. 6 indexed citations
8.
Fradley, Michael G., Angela DeMichele, Igor Makhlin, et al.. (2023). Adverse Cardiovascular Events Associated With Cyclin‐Dependent Kinase 4/6 Inhibitors in Patients With Metastatic Breast Cancer. Journal of the American Heart Association. 12(12). e029361–e029361. 27 indexed citations
9.
Dastgheyb, Sana, Kristine Kim, Abigail Doucette, et al.. (2022). Acute skin radiation toxicity seen with concurrent T-DM1: A single institutional report of 35 patients. The Breast. 67. 26–29. 2 indexed citations
10.
Makhlin, Igor, Nicholas P. McAndrew, E. Paul Wileyto, et al.. (2022). Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer. npj Breast Cancer. 8(1). 122–122. 5 indexed citations
11.
Makhlin, Igor, Melissa L. Martin, Jennifer Gillman, et al.. (2022). 18F-FDG PET/CT for the Evaluation of Therapy Response in Hormone Receptor–Positive Bone-Dominant Metastatic Breast Cancer. Radiology Imaging Cancer. 4(6). e220032–e220032. 13 indexed citations
12.
Braunstein, Evan M., Hang Chen, Igor Makhlin, et al.. (2021). Germline ERBB2/HER2 Coding Variants Are Associated with Increased Risk of Myeloproliferative Neoplasms. Cancers. 13(13). 3246–3246. 4 indexed citations
13.
Makhlin, Igor, Amy S. Clark, Paul Wileyto, et al.. (2021). Abstract PD9-10: Investigating the clinical utility of tumor mutational burden in predicting rapid progression and death in patients with metastatic breast cancer. Cancer Research. 81(4_Supplement). PD9–10. 1 indexed citations
14.
Makhlin, Igor & Kevin R. Fox. (2020). Oligometastatic Breast Cancer: Is This a Curable Entity? A Contemporary Review of the Literature. Current Oncology Reports. 22(2). 15–15. 24 indexed citations
15.
Makhlin, Igor & Angela DeMichele. (2020). On the Rise of Cyclin-Dependent Kinase Inhibitors in Breast Cancer: Progress and Ongoing Challenges. SHILAP Revista de lepidopterología. 9(2). 1 indexed citations
16.
Makhlin, Igor, Ryan Salinas, Daniel Zhang, et al.. (2019). Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR -mutant glioblastoma. CNS Oncology. 8(3). CNS43–CNS43. 37 indexed citations
17.
Vaught, Arthur J., Evan M. Braunstein, Jagar Jasem, et al.. (2018). Germline mutations in the alternative pathway of complement predispose to HELLP syndrome. JCI Insight. 3(6). 70 indexed citations
18.
Makhlin, Igor, Jiaru Zhang, Christopher Long, et al.. (2010). The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. British Journal of Urology. 108(2b). E84–90. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Irene Chong Breakdown of academic impact, for papers by Monica Onorati Breakdown of academic impact, for papers by Craig Vargo Breakdown of academic impact, for papers by Amy Guppy Breakdown of academic impact, for papers by Nazir Jamal Breakdown of academic impact, for papers by Alpaslan Özgün Breakdown of academic impact, for papers by Alessandra Bologna Breakdown of academic impact, for papers by Raj Nagarkar Breakdown of academic impact, for papers by Woon Sup Han Breakdown of academic impact, for papers by Mojca Persic
Rankless by CCL
2026